Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Austen Lavis"'
Autor:
Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to
Externí odkaz:
https://doaj.org/article/cdb9715afd524889a7ec2954a02ff624
Autor:
Austen Lavis, Margeaux Hodgson-Garms, John M. Mariadason, Natalia Vukelic, Paul Ioannidis, Andrew Weickhardt, David K. Lau, Laura J. Jenkins, Ian Y. Luk
Publikováno v:
BMC cancer. 22(1)
Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eae8041b4bfc614c151c78408ba4ef54
https://pubmed.ncbi.nlm.nih.gov/35501832
https://pubmed.ncbi.nlm.nih.gov/35501832
Autor:
David K. Lau, John M. Mariadason, Laura M. Jenkins, Andrew Weickhardt, Margeaux Hodgson-Garms, Natalia Vukelic, Austen Lavis, Ian Luk, Paul Ioannidis
BackgroundMutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10-20% of metastatic urothelial carcinomas, and can confer sensitivity to FGFR inhibitors such as BGJ398 and erdafitinib. However, responses to these agents are o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a28d37d5f58e2b24107906855f1e545
https://doi.org/10.21203/rs.3.rs-142420/v1
https://doi.org/10.21203/rs.3.rs-142420/v1
